Jazz Pharmaceuticals plc
Essential Information
Financial Summary (TTM)
Revenue
Net Income
Free Cash Flow
Shares Outstanding
EPS
ROIC
Dividend Per Share
Debt/FCF
In-Depth Analysis of Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals plc (JAZZ), listed on the NASDAQ, has a market capitalization of $7.10B. As of Apr 08, 2025, the stock is trading at $106.93 per share, offering investors a clear view of its current market value. Jazz Pharmaceuticals plc is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 12.36, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Jazz Pharmaceuticals plc also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Jazz Pharmaceuticals plc (JAZZ) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Jazz Pharmaceuticals plc is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Jazz Pharmaceuticals plc, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Jazz Pharmaceuticals plc is 4.78, offering insights into how much investors are paying for the company’s free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Jazz Pharmaceuticals plc (JAZZ) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company’s 10-K filings and do your own research before making any investment decisions.
Frequently Asked Questions about Jazz Pharmaceuticals plc (JAZZ)
Is Jazz Pharmaceuticals plc a good stock to buy?
Whether Jazz Pharmaceuticals plc (JAZZ) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
What is the fair value of Jazz Pharmaceuticals plc?
The fair value of Jazz Pharmaceuticals plc (JAZZ) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
What is Jazz Pharmaceuticals plc's SS Score?
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Jazz Pharmaceuticals plc. To access the full SS Score, consider upgrading your subscription.
How does Jazz Pharmaceuticals plc compare to other stocks in the industry sector?
Jazz Pharmaceuticals plc is a significant player in the industry sector, with a market capitalization of $7.10B and a competitive P/E ratio of 12.36. Investors should compare these metrics with industry peers to gauge whether Jazz Pharmaceuticals plc is outperforming or underperforming within its sector.